Are peptides steroids? Where the line really falls

What a steroid is, and what a peptide is

No. A steroid is a fat-soluble molecule built on a four-ring carbon skeleton. A peptide is a short chain of amino acids joined end to end. They are separate classes of molecule with separate shapes, built in separate ways. The two words describe structure, and structure alone.

Chemically the answer takes one sentence. A steroid is a fat-soluble molecule built around a four-ring carbon skeleton, the same core shape as cholesterol, testosterone and cortisol. A peptide is a chain of amino acids (the small building blocks your body also strings together to make proteins) joined end to end. Nothing about the first shape appears in the second. A peptide is not a steroid, and no amount of marketing changes that.

What each class does is separately documented. Anabolic steroids have been recognised for several decades by athletes and bodybuilders as promoting muscle growth and strength, and only relatively recently have they been revisited for clinical purposes, including treating the muscle wasting that comes with chronic disease and the loss of muscle mass in older people [1]. Peptides, meanwhile, are recognised for being highly selective and efficacious and at the same time relatively safe and well tolerated, which is why roughly 140 peptide therapeutics were in clinical trials as of a 2015 review of the field [2].

That second sentence is where most articles on this question stop, and it is where the trouble starts. "Relatively safe and well tolerated" is a statement about peptide drugs as a category in pharmaceutical development, compared against other categories of drug in development. It is not a promise attached to every molecule that happens to be a chain of amino acids, and the rest of this article is about the gap between those two readings. A molecule's shape does not tell you its potency, and the peptide class is where some of the most powerful hormone drugs in medicine live.

Not a steroid does not mean not a hormone

Many peptides are hormones. Growth hormone, luteinizing hormone and chorionic gonadotrophin are all peptide hormones. So are the gonadotrophin releasing hormone drugs goserelin, leuprolide and triptorelin, which are used to treat prostate cancer, breast cancer and endometriosis. Peptide is a chemical class, not a gentleness rating.

The US Anti-Doping Agency defines the category plainly: peptide hormones are hormones made of small chains of amino acids, produced by the body, circulating in the blood and binding to receptors on target organs and tissues [3]. Chorionic gonadotrophin and luteinizing hormone are both peptide hormones, and both play an important role in reproduction [3]. So are the corticotrophins, which cause the release of the stress hormone cortisol, and growth hormone itself, which regulates the production of many tissues in the body [3].

A second group sits alongside them. Releasing factors and secretagogues (compounds that tell the body to make and release a specific hormone of its own) work one step upstream: the pituitary gland secretes luteinizing hormone when it detects a luteinizing hormone releasing factor in the blood [3]. In males, luteinizing hormone and chorionic gonadotrophin stimulate the testes to produce more testosterone [3].

And here is the part that rarely survives into a "peptides versus steroids" comparison. Several gonadotrophin releasing hormone drugs, goserelin, leuprolide and triptorelin, are used to treat medical conditions including breast cancer, prostate cancer and endometriosis [3]. Those are not obscure compounds. They are among the most widely prescribed hormone drugs in oncology, they belong to the peptide hormones and releasing factors family, and what they are prescribed for is the deliberate, total shutdown of a sex hormone axis. The next section is what that looks like in a trial.

The claim that peptides do not suppress your own hormones

This is the single most repeated claim in the peptides-versus-steroids genre, and its most prescribed counterexample is a peptide. In a 610-patient phase 3 trial, monthly leuprolide held testosterone at or below 0.5 nanograms per millilitre at every monthly measurement from day 28 to day 364 in 96.4 percent of men.

Search the phrase and you will find it everywhere: peptides work with your body rather than overriding it, so unlike steroids they do not shut your own hormone production down. As a general statement about growth hormone secretagogues it has a reasonable basis. As a statement about peptides as a class it is simply false, and the trial that refutes it is large, randomised and thirty seconds away.

A 12-month phase 3 study randomised 610 patients with prostate cancer, median age 72, to one of three androgen deprivation regimens [4]. One arm received the peptide degarelix at 240 milligrams under the skin for the first month followed by monthly maintenance; another received the same drug at a higher maintenance dose; the third received leuprolide, 7.5 milligrams into the muscle every month [4]. Those are trial parameters, not a protocol anyone should copy.

The primary endpoint was suppression of testosterone to 0.5 nanograms per millilitre or below at every single monthly measurement from day 28 to day 364 [4]. In the intent-to-treat population it was achieved by 97.2 percent, 98.3 percent and 96.4 percent of patients in the three arms respectively [4]. For scale, median testosterone on entry was 3.93 nanograms per millilitre [4]. So a peptide, given once a month, took nineteen men in twenty from a normal reading down to roughly an eighth of it and held them there for a year.

That is not a side effect. It is the entire therapeutic point of the drug, which is what makes it such a clean counterexample: hormone suppression is not something the peptide class narrowly avoids, it is something part of the peptide class was designed to do.

What the evidence says about the muscle claim

A systematic review of 27 randomised study samples, in which 303 healthy young participants received growth hormone, found lean body mass rose by 2.1 kilograms while strength and exercise capacity did not seem to improve. Treated participants more often had soft tissue swelling and fatigue. Performance claims, the authors concluded, are not supported.

The other half of the comparison is the promise that peptides do what steroids do, more gently. The best-tested version of that promise is growth hormone, and it has been examined properly. A systematic review searched four databases for randomised controlled trials in healthy, community-dwelling people aged 13 to 45, and found 44 articles describing 27 study samples; 303 participants received growth hormone, representing 13.3 person-years of treatment in total [5]. They were young (mean age 27), lean and physically fit [5].

Lean body mass increased in the growth hormone recipients by 2.1 kilograms (95 percent confidence interval 1.3 to 2.9), which sounds like a result until you read the next clause: strength and exercise capacity did not seem to improve [5]. Lactate levels during exercise were significantly higher in two of the three studies that measured them, and treated participants more frequently experienced soft tissue swelling and fatigue than untreated ones [5]. The authors' conclusion is unambiguous: claims that growth hormone enhances physical performance are not supported by the scientific literature, and the available evidence suggests it may increase lean body mass without improving strength, may worsen exercise capacity, and may increase adverse events [5]. They also flag the honest limitation, which is that few of the studies evaluated athletic performance and the study protocols may not reflect real-world use [5].

None of that means peptides are weak. Where a peptide has been put through a proper trial, the effects can be large. Daily tesamorelin, a growth hormone releasing factor analogue, was tested in 412 patients with HIV over 26 weeks, and visceral fat fell by 15.2 percent against a 5.0 percent rise on placebo [6]. Once-weekly semaglutide was tested in 1,961 adults with overweight or obesity, and mean body weight fell 14.9 percent against 2.4 percent on placebo at week 68 [7]. "Peptide" is not a synonym for mild. It is a synonym for nothing at all.

Where steroids genuinely are different

The long-term human record is the real asymmetry. Among 140 male weightlifters, the 86 reporting at least two years of steroid use had a mean ejection fraction of 52 percent against 63 percent in non-users, more coronary plaque, and a plaque burden that tracked how long they had used.

Having spent four sections puncturing the easy version of the comparison, it is only fair to say where the asymmetry is real. Anabolic steroids have a documented long-term harm record that the research peptides do not, for the straightforward reason that people have been using steroids at scale for sixty years and somebody finally went and measured them.

A cross-sectional study recruited 140 experienced male weightlifters aged 34 to 54: 86 reporting at least two years of cumulative lifetime anabolic-androgenic steroid use, and 54 who had never used [8]. Using echocardiography and coronary CT angiography, the users showed reduced heart pumping function (mean ejection fraction, the share of blood the left ventricle expels per beat, 52 percent against 63 percent) and reduced relaxation function, both at P below 0.001 [8]. Users on drug at the time of evaluation looked worse than users currently off it [8]. Coronary artery plaque volume was higher in users than non-users (P = 0.012), and lifetime dose tracked plaque burden, with each additional 10 years of cumulative use associated with a 0.60 standard deviation rise in plaque volume rank (95 percent confidence interval 0.16 to 1.03) [8]. This design compares two groups at one moment, so it establishes association rather than proof of cause, and the authors describe the findings as an association throughout [8].

The pharmacology literature adds a note worth keeping. Doping with anabolic steroids can result in damage to health, as recorded meticulously in the former German Democratic Republic [1]. Even so, the same review argues it is important not to exaggerate the medical risks, but to emphasise to users that an attitude of personal invulnerability to their adverse effects is certainly misguided [1]. That is the tone this whole question deserves, in both directions.

Insulin is the peptide that ends the safety argument

Insulin is a peptide and one of the most dangerous drugs a person without diabetes can take. In a survey-based case series of 41 non-diabetic insulin users, 95.1 percent also used anabolic steroids, the group averaged 16.2 performance drugs a year, and 56.8 percent reported hypoglycaemia.

If one compound settles whether "peptide" implies "gentle", it is insulin, which is a peptide hormone and also among the most dangerous drugs a person without diabetes can inject. A 99-item internet survey posted to fitness, bodybuilding, weightlifting and anabolic steroid discussion boards in 2009 produced a case series of 41 non-diabetic insulin users [9]. The typical user was 30.7 years old, male in 97.6 percent of cases, and described himself as a recreational exerciser [9].

Hypoglycaemia (blood sugar dropping dangerously low, the characteristic insulin emergency) was reported by 56.8 percent of them, and one individual reported losing consciousness [9]. Most found the drug easy to get: 80.6 percent said so, sourcing it from friends, training partners and gym contacts in 40.5 percent of cases and from community pharmacies in 37.8 percent [9]. This is a self-selected internet survey of 41 people, so it describes a group of users rather than estimating how common any of this is, and the authors present it as a case series for exactly that reason [9].

The number that matters most for this article is a different one. Among those insulin users, 95.1 percent also used anabolic steroids, and the average person in the sample worked 16.2 performance-enhancing drugs into a yearly routine [9]. The peptide-versus-steroid frame imagines two populations choosing between two categories. In the one group anybody actually surveyed, the categories were stacked on top of each other by nearly everyone. The chemical boundary is real; the behavioural boundary mostly is not.

The legal line is real and it does not mean what people think

Anabolic steroids are named in Schedule III of the federal Controlled Substances Act. Most research peptides are not scheduled at all, which reads as more permissive and is not. Selling peptide hormones in dietary supplements is illegal, which is precisely why they are sold as research chemicals not for human use.

Here the two classes really do part company, and the difference is usually reported backwards. In the United States, Schedule III of the Controlled Substances Act lists, at subsection (e), "anabolic steroids" [10]. Schedule III is defined as covering substances with a potential for abuse less than those in Schedules I and II, a currently accepted medical use in treatment in the United States, and a potential for moderate or low physical dependence or high psychological dependence [10]. Being on a schedule at all means possession and distribution are governed by federal drug law.

Most peptides are not on any schedule. That is regularly presented as peptides being the legal option, and it is a misreading, because not being a controlled substance is not the same as being lawfully sold. It is illegal to sell peptide hormones in dietary supplements, and they are not approved by the FDA for over-the-counter self-treatment [3]. The workaround is visible on any vendor site: many websites sell experimental peptide hormones marketed as "research chemicals", "for research use only" or "not for human use" [3]. That labelling is not a certification of anything. It is the phrasing that keeps a product outside the rules that would otherwise apply to it, and the safety of such products has not been established [3].

So the honest summary is two different unlawful positions rather than one lawful and one not. A steroid is a scheduled drug you need a prescription for. A research peptide is usually an unapproved drug sold under a disclaimer that says it is not for the use everyone buying it intends. Neither of those is "legal" in the sense people mean when they ask.

In sport, the distinction disappears entirely

Anti-doping files them as neighbours. On the 2026 Prohibited List, S1 is anabolic agents and S2 is peptide hormones, growth factors and related substances. Peptide hormones and releasing factors are prohibited at all times under S2.2, and peptides that fit nowhere else, BPC-157 among them, fall under S0.

Anyone competing under anti-doping rules can skip the chemistry, because the rules already collapsed the distinction. The World Anti-Doping Agency Prohibited List is the international standard for what is prohibited in sport, it is updated annually after consultation, and each new version takes effect on 1 January [11]. On the 2026 List, section S1 is anabolic agents and section S2 is peptide hormones, growth factors and related substances [12]. They are adjacent entries in the same document.

Peptide hormones and releasing factors are prohibited at all times, in and out of competition, under section S2.2 [3]. The list of S2 agents grows every year, and here is the clause that catches people: even if a substance is not specifically listed, it may still be prohibited if it has "a similar chemical structure or similar biological effect(s)" [3]. The 2026 revision is a live example, adding pegmolesatide as an instance of a new EPO-mimetic agent [12].

Peptides that do not fit S2 are not thereby free. Exogenous peptides and growth factors are listed under S2, and other peptides, such as BPC-157, are prohibited under S0, non-approved substances [13]. Being an unapproved research chemical is the condition that puts a compound in S0, not an exemption from the List. The practical instruction from the agency is the same either way: check the current status of a specific substance on GlobalDRO rather than trusting any article, this one included [3].

Which leaves a better question than the one this article started with. "Is it a steroid" sorts molecules into two boxes and tells you almost nothing. What is this molecule, what has been tested in humans, at what dose, with what measured, and who says it is allowed is five questions, and each of them has an answer you can go and read.